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R 
andomized controlled trials (RCTs) on acute ischemic stroke (AIS) due to large vessel occlusion 
(LVO) established the superiority of endovascular 
thrombectomy (EVT) in addition to the best medical management, including intravenous thrombolysis, over 
best 
medical management alone within 6 hours from symptom onset.1–6 Some of these trials enrolled patients 
up to 
85 or 12 hours2 from symptom onset. The HERMES collaboration individual patient data meta-analyses7,8 
of the 
first 5 RCTs1–5 showed that the probability of functional 
independence (modified Rankin Scale [mRS], 0–2) at 3 
months was 46.1%,7 and that although the magnitude 
of benefit declines as time from symptom onset to groin 
puncture increases, the treatment benefit also remains 
beyond 6 hours after stroke onset, but it becomes nonsignificant after 7.3 hours.8 
More recent trials demonstrated that the time window 
for endovascular treatment can be extended up to 169 
or 24 hours10 from the last time the patient was known 
to be well, when the selection is based on neuroimaging evaluation showing a salvageable penumbra9 or a 
mismatch between clinical deficit and infarct size.10 As a 
result, current guidelines11,12 recommend thrombectomy 
in the 6- to 24-hour time window for patients meeting 
the DAWN10 and DEFUSE-3 trial9 criteria. The DAWN 
and DEFUSE-3 trials9,10 focused on patients who suffered mainly from unwitnessed or wake-up stroke. 
Only 
10% of treated patients and 14% of control patients 
in the DAWN study10 and 34% and 39% of patients 
and controls, respectively, in the DEFUSE-3 trial9 were 
treated beyond 6 hours after witnessed stroke onset. 
The aim of this study is to evaluate the outcome and 
safety of EVT in patients with anterior circulation AIS 
due to a proximal intracranial artery occlusion who were 
treated beyond 6 hours from known symptom onset in a 
large real-world cohort of patients included in the Italian 
Registry of Endovascular Thrombectomy. 
METHODS 
The source of data is the Italian Registry of Endovascular Stroke 
Treatments, a multicenter, prospective, observational internetbased registry which includes patients 
treated with thrombectomy since 2011. The purposes, organization, and structure 
of the Registry were previously described in more detail.13,14 
This registry was implemented to collect baseline and outcome 
information for all treated patients and to share experiences 
and operational protocols, with the aim to improve and standardize quality of care delivered throughout 
the national territory. Centers included in the registry were required to accept 
the rules of the registry, including consecutive registration of all 
patients with stroke receiving endovascular procedures, participation in regular meetings, and 
incorporation of the proposed 
operational protocols in their routine local practice. The data 
that support the findings of this study are available from the corresponding author upon reasonable 
request. Ethical approval 
from the ethics committees of the participating centers and 
patient informed consent were obtained. According to national 
guidelines,15 patients admitted within 6 hours of stroke onset 
were considered eligible for endovascular treatment if the following inclusion criteria were fulfilled: LVO 
documented on 
CT angiography (CTA), a baseline CT Alberta Stroke Program 
Early CT Score (ASPECTS) ≥6, and a prestroke mRS score 
≤2. However, in selected patients, endovascular procedure was 
conducted beyond 6 hours after stroke onset. The decision to 
treat beyond the standard therapeutic window was individualized on the basis of findings obtained from 
admission brain noncontrast CT scans, CTA of cervical vessels, head single-phase 
CTA or preferably, multi-phase CTA of intracranial vessels and 
CT perfusion (CTP). The extension of early ischemic changes 
was evaluated on noncontrast CT by using ASPECTS. Collateral 
supply was graded on a 4-point scale for single-phase CTA,16 
in which collaterals were categorized as poor (scores, 0–1) 
and good (scores, 2–3), and on a 6-point scale for multi-phase 
CTA, in which collaterals were classified as poor (grade, 0–3) 
and good (scores, 4–5).17 Cerebral blood flow, cerebral blood 
volume, and mean-transit-time CTP maps were generated for 
each patient. CTP was evaluated according to the classical CTP 
mismatch model18: (1) mean-transit-time lesion indicating total 
hypoperfusion; (2) cerebral blood volume lesion referring to 
infarct core; and (3) mean-transit-time-cerebral blood volume 
representing ischemic penumbra. CTP mismatch was defined 
as the difference between total hypoperfusion and infarct core 
size and was evaluated by visual inspection. For each modality, 
patients were judged to be candidates for EVT based on the 
following criteria: (1) noncontrast CT ASPECTS ≥6; (2) good 
collateral circulation (single-phase CTA collateral score of 2–3 
or multi-phase CTA collateral score of 4–5); (3) CTP mismatch 
with an infarct core size ≤50% of total hypoperfusion extent 
or involving less than one-third of the MCA territory extent 
according to Turk et al19 and to mismatch ratio model. Patients 
with noncontrast CT ASPECTS <6, with poor collaterals, without CTP mismatch or with CTP mismatch but an 
infarct core 
size >50% of total hypoperfusion extent or involving more than 
one-third of the MCA territory extent, with an inability to complete multimodal CT protocol at baseline or 
with poor CT quality 
were excluded. The same inclusion and exclusion criteria were 
also used for the selection of patients treated with endovascular therapy within 6 hours of stroke onset. 
We extracted data for 
patients with LVO (occlusion of the internal carotid artery, and 
middle cerebral artery M1 or M2), treated within and beyond 6 
hours of stroke onset between 2011 and 2017. Patients with 
an occlusion of middle cerebral artery M3, anterior cerebral 
artery, or the posterior circulation were excluded. To include 
only cases definitely treated beyond 6 hours, patients with 
unknown onset of stroke (due to patients being unconscious, 
disoriented or aphasic, when a witness was not available, or 
when the patient awoke with stroke symptoms) were excluded 
from this analysis. For each patient, demographics, stroke risk 
factors, prestroke mRS, stroke severity (National Institutes of 
Health Stroke Scale [NIHSS] at admission), baseline neuroimaging, and data on endovascular treatment 
were collected. 
Clinical follow-up was assessed by mRS at 3 months. The primary outcome measure was the score on mRS 
at 90 days, 
as assessed by a local trained neurologist through in-person 
visit, or through a phone standardized interview when a face-toface assessment was not possible. We 
examined the following 
dichotomizations of the mRS score: 0 to 1 versus 2 to 6, 0 to 2 
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versus 3 to 6, and 0 to 3 versus 4 to 6. For efficacy measures, 
arterial recanalization was rated according to the Thrombolysis 
in Cerebral Infarction (TICI) score.20 Successful recanalization 
was defined as TICI score 2b or 3, while TICI 3 defined as 
complete recanalization. Symptomatic intracranial hemorrhage 
(sICH) was defined as any intracranial hemorrhage associated 
with a 4 point increase in the 24 hours NIHSS score, according 
to the ECASS II definition.21 SICH, procedural adverse events 
(subarachnoid hemorrhage and vessel dissection), and death 
rate were considered safety measures. 
Statistical Analysis 
Data were presented as absolute numbers, percentages, 
mean±SD if normally distributed or median and interquartile 
ranges, as appropriate. Dichotomous variables were compared 
using the χ2 test, while continuous variables were compared 
by Student t test or Mann-Whitney U test as appropriate on 
the basis of data distribution. A multivariable logistic regression 
analysis to adjust for sex, age, history of hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, 
smoking status (current or former), NIHSS score at entry, site of occlusion, and 
ASPECTS score, was also run to compare outcome and safety 
measures between subgroups of patients treated at different times. The functional outcome was further 
evaluated with 
ordinal logistic regression, taking the whole range of mRS into 
account as a dependent variable adjusted for the above variables. The adjusted common odds ratio (OR) 
and corresponding 95% CI for a shift in the direction of a better outcome on 
the modified Rankin scale was, therefore, calculated. A P<0.05 
was considered significant for all tests. 
RESULTS 
Out of 3057 patients with AIS whose time at stroke 
onset was known, 327 (164 women and 163 men) 
treated beyond 6 hours after symptom onset were 
included in the analysis. Their mean age was 66.8±14.9 
years. Good collaterals were identified by single-phase 
CTA in 209 and by multi-phase CTA in 118 patients. All 
patients had a CTP mismatch. Of these, infarct core size 
was considered ≤50% of total hypoperfusion extent in 
174 and less than one-third the middle cerebral artery 
territory extent in 153 patients. Table 1 summarizes 
clinical and demographic data of included patients. The 
median NIHSS score at baseline was 16 (interquartile range, 12–20). The most frequent site of occlusion 
was the middle cerebral artery M1 (45%). The median 
onset-to-groin puncture time was 430 minutes (interquartile range, 390–570). Two hundred and one 
patients 
(61.5%) were treated between 361 and 480 minutes, 
55 (16.8%) between 481 and 600 minutes, 22 patients 
(6.7%) between 601 and 720 minutes, and 49 patients 
(15%) beyond 12 hours (up to 24 hours) from symptoms 
onset. Functional independence (mRS, 0–2) at 90-day 
follow-up was achieved by 41.3% of cases (Table 2). The 
proportion of patients with stroke with complete recovery 
or minimal disability at 3 months (mRS, 0–1) was 26.9%, 
while 53.2% of patients survived with a disability range of 
0 to 3. The 3-month case fatality rate was 17.1%. SICH 
occurred in 22 patients (6.7%). A successful recanalization was achieved in 232 patients (70.9%), while TICI 
score of 3 was recorded in 167 subjects (51.1%). 
Outcomes by final TICI score are reported in Table 3. 
When focusing on patients with internal carotid artery 
and M1 occlusion (excluding those with M2 occlusion), 
the findings concerning outcomes were not significantly 
different, since the proportions of patients with 90-day 
mRS 0 to 1, 0 to 2, and 0 to 3 were 25.4% (72/284), 
39.1% (111/284), and 50.4% (143/284), respectively. 
Twenty-one patients (7.4%) had sICH, and the 3-month 
case fatality was 17.3% (49/284). Complete recanalization was achieved in 146 (51.4%) of patients, and TICI 
2b/3 was recorded in 200 (70.4%). 
We compared outcome data between patients who 
underwent EVT beyond 6 hours and patients with AIS 
treated within 6 hours of symptom onset extracted by the 
Italian Registry with the same selection criteria (Table 1). This 
population included 2730 patients (1352 men and 1378 
women) with a mean age of 69.73±13.6 SD and a median 
NIHSS at baseline of 18 (interquartile range, 13–21). 
Patients treated beyond 6 hours were significantly 
younger than patients treated earlier (P<0.001), had 
a lower baseline NIHSS score (P<0.01), and a lower 
Table 1. Clinico-Demographic Characteristics, and Outcome 
of Patients Treated Within and Beyond 6 Hours 
Beyond 6 Hours Within 6 Hours 
Sex, men, n (%) 163 (49.8) 1352 (49.5) 
Age, mean±SD 66.8±14.9* 69.73±13.7* 
History, n/N (%) 
Hypertension 186/319 (58.3) 1625/2585 (62.9) 
Diabetes mellitus 51/317 (16.1) 408/2585 (15.8) 
Dyslipidemia 67/317 (21.1) 641/2585 (24.8) 
Atrial fibrillation 92/318 (28.9) 878/2584 (34.0) 
TIA/stroke (last 3 mo) 12/327 (3.6) 117/2720 (4.3) 
Smokers 67/317 (21.1) 636/2585 (24.6) 
History of malignancy 16/320 (5.0) 155/2725 (5.7) 
Baseline NIHSS (median, IQR) 16, 12–20† 18, 13–21† 
ASPECTS (median, IQR) 8, 7–10‡ 9, 8–10‡ 
IV thrombolysis, n/N (%) 25/327 (27.6)§ 1774/2730 (65.0)§ 
 Onset to groin puncture time 
(median, IQR) 
430 (390–570)* 220 (170–273)* 
Site of occlusion n (%) Total number 327‡ Total number 2730‡ 
 Middle cerebral artery, 
proximal (M1) 
147 (45.0) 1338 (49.0) 
Middle cerebral artery, distal (M2) 43 (13.1) 421 (15.4) 
Carotid T 52 (15.9) 446 (16.3) 
Tandem occlusion 85 (26.0)† 525 (12.9)† 
ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile 
range; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke 
Scale; and TIA, transient ischemic attack. 
*P<0.001, †P<0.01, ‡P<0.05, §P<0.0001. 
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median ASPECTS score. No significant differences were 
found regarding vascular risk factors and comorbidities. A tandem occlusion was more frequent in patients 
treated later (P<0.01). 
The comparison of outcomes in patients treated 
beyond and within 6 hours was reported in Table 2. The 
common adjusted OR for a shift toward a better outcome 
was 1.59 (1.27–2.02) in favor of patients treated earlier. 
The multivariable logistic regression analysis showed 
that the probability of surviving with mRS 0 to 1 (OR, 
0.52 [95% CI, 0.38–0.7]), mRS 0 to 2 (OR, 0.58 [95% 
CI, 0.43–0.77]), or mRS 0 to 3 (OR, 0.59 [95% CI, 0.44– 
0.78]) was significantly lower in patients treated beyond 
6 hours. No differences were found regarding recanalization rates and safety outcomes. 
We compared baseline characteristics and outcomes 
(Table 4) of patients treated between 6 and 12 hours and 
those treated beyond 12 hours. We found no significant 
differences between these 2 groups, except for a higher 
probability for survival with mRS 0 to 3 in the group of 
patients treated 6 to 12 hours after stroke onset. 
DISCUSSION 
In this study, we analyzed outcome and safety data for 
patients with AIS treated with EVT beyond 6 hours from 
witnessed symptom onset in a real-world setting. EVT 
eligibility was decided by a combination of collateral 
score and CTP mismatch assessed by visual inspection. 
A qualitative evaluation of CTP mismatch was used due 
to the limited availability of automated software programs 
for a threshold-based calculation of infarct core, ischemic penumbra volumes, and of mismatch ratio 
(target 
mismatch) at the time of patient enrollment in Italy. We 
adopted an integrated approach, including CTA collateral 
score and CTP mismatch; this approach has recently 
been demonstrated to be promising for the selection of 
patient with AIS candidates for reperfusion therapies.22,23 
Mortality and sICH of patients treated beyond and 
within the conventional time window were not significantly different, suggesting that patient with AIS 
treated 
Table 2. Outcome and Safety Data 
Beyond 6 Hours 
(n=327) 
Within 6 Hours 
(n=2730) AdjOR (95% CI) 
Shift analysis 1.57 (1.25–1.98) 
Outcomes, n (%) 
mRS 0–1 88 (26.9) 908 (33.3) 0.52 (0.38–0.7) 
mRS 0–2 135 (41.3) 1271 (46.6) 0.58 (0.43–0.77) 
mRS 0–3 174 (53.2) 1617 (59.2) 0.59 (0.44–0.78) 
Death 56 (17.1) 443 (16.2) 1.19 (0.8–1.7) 
TICI 2b/3 232 (70.9) 1999 (73.2) 0.7 (0.6–1.01) 
TICI 3 167 (51.1) 1505 (5.1) 0.78 (0.6–1.003) 
sICH 22 (6.7) 189 (6.9) 0.97 (0.58–1.6) 
Data on final recanalization were not available for 3 patients treated beyond 6 
hours. AdjOR indicates odds ratio adjusted for age, sex, site of occlusion, baseline, 
stroke severity, atrial fibrillation, hypertension, diabetes mellitus, dyslipidemia, 
smoke; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; 
and TICI, Thrombolysis in Cerebral Infarction. 
Table 3. Outcome and Safety Data of Patients Treated 
Beyond 6 Hours According to Final TICI Score 
TICI 0 TICI 1 TICI 2a TICI 2b TICI 3 
No. of patients 27 22 43 65 167 
Outcome n (%) 
Death 11 (40.7) 8 (36.4) 5 (11.6) 10 (15.4) 20 (12) 
sICH 0 2 (9.1) 3 (7) 6 (9.2) 10 (6) 
3-month mRS 
mRS 0–1 1 (3.7) 2 (9.1) 7 (16.3) 18 (27.7) 60 (35.9) 
mRS 0–2 3 (11.1) 3 (13.6) 19 (44.2) 22 (33.8) 88 (52.7) 
mRS 0–3 6 (22.2) 6 (27.3) 26 (6.5) 30 (46.2) 106 (63.5) 
Data on final recanalization were not available for 3 patients. mRS indicates 
modified Rankin Scale; TICI, Thrombolysis in Cerebral Infarction; and sICH, 
symptomatic intracranial hemorrhage. 
Table 4. Demographic, Baseline Clinical Characteristics, 
Site of Occlusion, Interventional Workflow, and Outcome 
of Patients Treated Beyond 6 Hours, According to Onset to 




 (n=49) AdjOR (95%CI) 
Sex, men n (%) 135 (48.6) 28 (57.1) 
Age (mean±SD) 66.7 (15.2) 67.2 (13.1) 
History, n/N % 
Hypertension 159/273 (58.2) 27/46 (58.7) 
Diabetes mellitus 47/270 (17.4) 4/47 (8.5) 
Dyslipidemia 55/270 (20.4) 12/47 (25.4) 
Atrial fibrillation 82/271 (30.2) 10/47 (21.2) 
Smoker 56/270 (20.7) 11/47 (22.2) 
Median (IQR) 
baseline NIHSS 
16 (12–20) 15.5 (10–22.75) 
Site of occlusion, n (%) 
M1 131 (47.1) 16 (32.7) 
M2 37 (13.3) 6 (12.2) 
Carotid T occlusion 43 (15.5) 9 (18.4) 
Tandem occlusion 67 (24.1) 18 (36.7) 
Median (IQR) time 





Outcome, n (%) 
mRS 0–1 78 (28.1) 10 (20.4) 2 (0.8–4.9) 
mRS 0–2 118 (42.4) 17 (34.7) 2 (0.9–4.3) 
mRS 0–3 154 (55.4) 20 (40.8) 2.6 (1.2–5.5) 
Death 47 (16.9) 9 (18.4) 1.04 (0.4–2.7) 
TICI 2b/3 198 (71.2) 34 (69.4) 0.9 (0.4–1.9) 
TICI 3 144 (51.8) 23 (46.9) 1.1 (0.5–2.2) 
sICH 17 (6.1) 5 (10.2) 0.5 (0.2–1.8) 
AdjOR indicates adjusted odds ratio; mRS, modified Rankin Scale; sICH, 
symptomatic intracranial hemorrhage; and TICI, Thrombolysis in Cerebral 
Infarction. 
*P<0.0001. 
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later from onset, selected for EVT using the eligibility criteria described above, had safety profiles 
comparable to 
patient with AIS treated earlier. 
Patients who underwent EVT beyond 6 hours (within 
24 hours) from symptom onset had a 27% probability 
to survive with no or very mild disability and a 41.3% 
probability of functional independence at 3 months after 
stroke. These results are similar to those reported from a 
meta-analysis on individual patients data8 from 5 RCT trials1–5 that identified 147 patients with stroke due 
to LVO 
of the anterior circulation treated beyond 6 hours either 
with mechanical thrombectomy (n=77) or with standard 
medical care (n=70); the proportion of patients surviving with functional independence (mRS, 0–2) was 39% 
for patients who underwent endovascular treatment and 
24.4% in the control (best medical therapy) group. Our 
findings were also consistent with data from previous 
observational studies testing the possibility to extend the 
time window for EVT beyond 6 hours by using advanced 
brain imaging, including CTP and magnetic resonance 
diffusion-weighed imaging (MR-DWI) and perfusionweighted imaging (MR-PWI).17,24–33 CTP, MR-DWI, 
and 
MR-PWI selection criteria were established by visual 
inspection in all but one23 of these articles. In one study, 
advanced imaging was adopted in 34% of patients.33 In 
these studies, the number of included patients ranged 
from 2125 to 2682; the site of occlusion involved anterior 
circulation25,26,28–33 and either anterior or posterior circulation;17,24,27,28 patients were treated 
beyond 8 hours,24,26,29,30 
beyond 7 hours,17 beyond 6 hours from symptom onset, 
or, more frequently, from time last seen well25,27,28,31–33; the 
proportion of patients achieving a good functional outcome (90-day mRS, 0–2) ranged from 32%31 to 
62%,33 
and the case fatality rate ranged from 13% to 26.2% 
(Table 5). The utility of advanced imaging in the selection of late-presenting patients with AIS with LVO was 
further confirmed by a recent single-center study showing a good outcome in 36% of patients when those 
with 
baseline mRS >2 were excluded.34 
In our study, the comparison between patients treated 
within and beyond 6 hours after symptom onset demonstrated that the chance of good clinical outcome 
declined with longer onset to treatment intervals, without significantly affecting safety outcomes. Recent 
late 
windows trials9,10 showed a favorable outcome rate of 
49% and 45%, respectively, similar to that reported by 
the HERMES Collaboration meta-analysis of early window trials.7 However, it should be acknowledged that 
the HERMES study incorporated early window patients 
selected with CT and CTA without further advanced 
imaging, leading to the potential inclusion of a proportion of patients with a matched core and penumbra: 
this 
could have blunted the differences in outcome between 
patients treated in the early and late time windows. In 
fact, in RCTs enrolling patients in early time windows with 
advanced imaging (EXTEND IA and SWIFT PRIME),1,3 
the rates of good outcome were found to be 71% and 
63%, respectively.35 Therefore, these observations 
could explain the decrease in good outcomes over time 
reported in our study in which both early- and late-treated 
patients were selected with advanced imaging. Additionally, these findings seem to indicate that time 
remains a 
key variable in predicting clinical outcome on a population basis, but not at individual level, where it is just 
one 
of the many variables affecting outcome, reinforcing the 
Table 5. Overview of Observational Studies on EVT Beyond 6 Hours 
No. of Patients Age* Baseline NIHSS† mRS 0–2‡ Death‡ sICH 
Natarajan et al24 30 72 (range 24–91) 12 (range, 5–22) 33.3 20 10 
Abou-Chebl25 21 59.4 (17.2) 17.8 (5.5) mean (SD) 43 23.8 (30-day) 9.5 
Jovin26 169 64 (16) 17 (range 10–29) 40 25 10 
Jung27 128 61.1 (15.1) 15 (range 2–36) 35.2 26.2 3.7 
Turk, 201317 70 64.9 15.1 45.5 21.2 5.6 
Abilleira et al28 154 65 (14.2) 17 (13–21) 35.7 23.4 8.4 
Gratz29 22 67.1 (14.5) 16.5 (range 8–22) 36.4 18.2 9.1 
Aghaebrahim et al30 128 64 (13.6) 14 (5.4) mean (SD) 50 22 5.5§ 
Tsurukiri et al31 31 74 (9) 17 (13–20) 32 13 10 
Mokin et al32 248 66.1 (14.6) 16 (13–20) 46.2 21.6 11 
69.9 (14) 16 (12–20) 
Alsahli et al33 56 72 (60–82) 15 (8–20) 62 14 7 
Present study 327 66.8 (14.9) 16 (12–20) 41.3 17.1 6.7 
EVT indicates endovascular thrombectomy; mRS, modified Rankin Scale; NIHSS, National Institutes of 
Health Stroke Scale; and sICH, symptomatic intracranial 
hemorrhage. 
*Mean (SD) unless otherwise stated. 
†Median (IQR) unless otherwise stated. 
‡90-day unless otherwise stated. 
§In this study, only data about hemorrhagic transformation PH type was reported. 
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view that a selection of patients only based on time is no 
longer justified.36 
Taken together, the data obtained in the present study 
suggest the possibility to extend the time window for 
EVT beyond 6 hours after onset in the real world using 
a combined approach based on the concomitant visual 
assessment of CTA collateral extent and CTP mismatch 
even in those centers not equipped with automated software programs able to calculate the different 
parameters 
of target mismatch. Nevertheless, the lack of a control 
group of untreated patients limits the strength of these 
findings since it precludes an actual assessment of treatment effect, the comparison with previous RCTs 
and as a 
consequence, the generalization of our results. 
This study has other limitations, most of which are 
inherent to its observational nature. First, despite central monitoring of data quality and completeness, it is 
not possible to exclude reporting biases in a multicenter 
prospective national registry with self-reported clinical 
and outcome data. Second, the visual, qualitative interpretation of radiological findings could represent 
another 
drawback of the current analysis, since it is now widely 
accepted that threshold-based quantitative parameters 
obtained with automated software programs represent 
the best method for correctly identifying patients with 
AIS who can benefit from EVT beyond 6 hours after 
onset.9,10,12 However, our study showed a safety profile 
similar to that reported in the setting of clinical trials.9,10 
Although RCTs remain the gold standard in the assessment of intended effects of interventions, 
observational 
studies can be useful for providing important information 
under everyday circumstances. 
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